Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

428 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma.
Monson KR, Ferguson R, Handzlik JE, Morales L, Xiong J, Chat V, Dagayev S, Khodadadi-Jamayran A, Simpson D, Kazlow E, Bunis A, Sreenivasaiah C, Ibrahim M, Voloshyna I, Ouwerkerk W, Luiten RM, Capone M, Madonna G, Lu Y, Shao Y, Pavlick A, Krogsgaard M, Mehnert J, Tang H, Dolfi S, Tenney D, Haanen JBAG, Gajewski TF, Hodi FS, Flaherty KT, Couts K, Robinson W, Puzanov I, Ernstoff MS, Rahma O, Postow M, Sullivan RJ, Luke JJ, Ascierto PA; IO-GEM Consortium; Osman I, Kirchhoff T. Monson KR, et al. Among authors: flaherty kt. Nat Med. 2025 Jun 5. doi: 10.1038/s41591-025-03699-3. Online ahead of print. Nat Med. 2025. PMID: 40473950
Mutation-driven drug development in melanoma.
Flaherty KT, Hodi FS, Bastian BC. Flaherty KT, et al. Curr Opin Oncol. 2010 May;22(3):178-83. doi: 10.1097/cco.0b013e32833888ee. Curr Opin Oncol. 2010. PMID: 20401974 Free PMC article. Review.
Inhibition of mutated, activated BRAF in metastatic melanoma.
Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Flaherty KT, et al. N Engl J Med. 2010 Aug 26;363(9):809-19. doi: 10.1056/NEJMoa1002011. N Engl J Med. 2010. PMID: 20818844 Free PMC article. Clinical Trial.
Targeted molecular therapy in melanoma.
Puzanov I, Flaherty KT. Puzanov I, et al. Among authors: flaherty kt. Semin Cutan Med Surg. 2010 Sep;29(3):196-201. doi: 10.1016/j.sder.2010.06.005. Semin Cutan Med Surg. 2010. PMID: 21051014 Review.
Biological challenges of BRAF inhibitor therapy.
Puzanov I, Burnett P, Flaherty KT. Puzanov I, et al. Among authors: flaherty kt. Mol Oncol. 2011 Apr;5(2):116-23. doi: 10.1016/j.molonc.2011.01.005. Epub 2011 Feb 16. Mol Oncol. 2011. PMID: 21393075 Free PMC article. Review.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Chapman PB, et al. Among authors: flaherty kt. N Engl J Med. 2011 Jun 30;364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5. N Engl J Med. 2011. PMID: 21639808 Free PMC article. Clinical Trial.
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Sosman JA, et al. Among authors: flaherty kt. N Engl J Med. 2012 Feb 23;366(8):707-14. doi: 10.1056/NEJMoa1112302. N Engl J Med. 2012. PMID: 22356324 Free PMC article. Clinical Trial.
428 results